文献速递造血干细胞移植与细胞治疗血栓与止血

异基因造血细胞移植后环磷酰胺可减轻既往纳武利尤单抗治疗诱导的免疫激活

Posttransplant cyclophosphamide after allogeneic hematopoietic cell transplantation mitigates the immune activation induced by previous nivolumab therapy.
PubMed 文献 · Leukemia · 2020-05-11

研究探讨既往纳武利尤单抗暴露对异基因造血细胞移植后早期T细胞重建的影响,以及不同移植物抗宿主病预防方案的调节作用。所有纳武利尤单抗暴露患者移植后56天内血浆中仍可检测到纳武利尤单抗,第21天仍能结合并阻断T细胞上的PD-1。他克莫司/西罗莫司组中纳武利尤单抗暴露患者严重急性移植物抗宿主病发生率更高且效应T细胞特征更明显,而移植后环磷酰胺组中无论是否暴露,急性移植物抗宿主病风险和T细胞特征相似。

要点

  • 纳武利尤单抗暴露患者移植后56天内血浆中仍可检测到纳武利尤单抗
  • 移植后第21天残留纳武利尤单抗仍能结合并阻断T细胞上的PD-1
  • 移植后环磷酰胺可减轻纳武利尤单抗诱导的T细胞激活,降低急性移植物抗宿主病风险

核心结论

  • 纳武利尤单抗在移植后持续存在于血浆中,结合异基因T细胞并产生增加的T细胞激活。
  • 这种T细胞激活状态可通过使用移植后环磷酰胺减轻,从而降低急性移植物抗宿主病风险。

研究设计与样本

  • 研究纳入接受异基因造血细胞移植且既往使用纳武利尤单抗的患者,比较他克莫司/西罗莫司与移植后环磷酰胺两种移植物抗宿主病预防方案对早期T细胞重建的调节作用。

主要发现

  • 所有纳武利尤单抗暴露患者移植后56天内血浆中可检测到循环纳武利尤单抗。
  • 移植后第21天残留纳武利尤单抗能结合并阻断T细胞上的PD-1,诱导T细胞激活。
  • 他克莫司/西罗莫司组中,纳武利尤单抗暴露患者较抗PD-1未暴露患者严重急性移植物抗宿主病发生率更高,效应T细胞特征更明显。
  • 移植后环磷酰胺组中,无论既往是否暴露于纳武利尤单抗,急性移植物抗宿主病风险和T细胞特征相似。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients receiving an allogeneic hematopoietic cell transplantation (allo-HCT) after the use of PD-1 inhibitors seem to be at a higher risk of developing acute graft-versus-host disease (aGHVD) through etiopathogenetic mechanisms not fully elucidated. Herein, we investigated the effect of nivolumab administered prior to allo-HCT on the following early T-cell reconstitution and its modulation by the GVHD prophylaxis (tacrolimus/sirolimus vs. posttransplant cyclophosphamide [PTCY]). In all nivolumab-exposed patients we detected circulating nivolumab in plasma for up to 56 days after allo-HCT. This residual nivolumab was able to bind and block PD-1 on T-cells at day 21 after allo-HCT, inducing a T cell activation that was differentially modulated depending on the GVHD prophylactic regimen. Among patients receiving tacrolimus/sirolimus, nivolumab-exposed patients had a higher incidence of severe aGVHD and a more effector T-cell profile compared with anti-PD-1-naïve patients. Conversely, patients receiving PTCY-based prophylaxis showed a similar risk of aGVHD and T-cell profile irrespective of the previous nivolumab exposure. In conclusion, nivolumab persists in plasma after transplantation, binds to allogeneic T cells and generates an increased T-cell activation. This T-cell activation status can be mitigated with the use of PTCY, thus reducing the risk of aGVHD.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Nieto JC, Roldán E, Jiménez I, et al. Posttransplant cyclophosphamide after allogeneic hematopoietic cell transplantation mitigates the immune activation induced by previous nivolumab therapy. Leukemia. 2020. PMID: 32393842. doi:10.1038/s41375-020-0851-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。